Trials / Completed
CompletedNCT02655237
A Phase 3 Study to Evaluate the Efficacy and Safety of Relugolix (TAK-385) 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
A Multicenter, Randomized, Double-Blind, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of Oral TAK-385 40 mg Compared With Leuprorelin in the Treatment of Uterine Fibroids
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 281 (actual)
- Sponsor
- Takeda · Industry
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy of Relugolix (TAK-385) 40 mg administered orally once daily for 12 weeks, compared with leuprorelin injection (once every 4 weeks, 1.88 mg or 3.75 mg subcutaneously \[SC\]/time) in patients with uterine fibroids.
Detailed description
The drug tested in this study was called Relugolix (TAK-385). Relugolix was tested to treat people who had uterine fibroids. The study enrolled 281 patients. Participants received relugolix placebo and leuprorelin acetate placebo in run in period for 3 to 6 weeks. After run-in period, participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups in 1:1 ratio: * Relugolix 40 mg * Leuprorelin 1.88 or 3.75 mg Participants received relugolix tablets once daily along with leuprorelin 1.88 mg or 3.75 mg subcutaneous injection once in 4 weeks for 24 weeks in treatment period. This multi-center trial was conducted in Japan. The overall time to participate in this study was approximately 32 to 40 weeks including run-in period of 3 to 6 weeks and a treatment period of 24 weeks. Participants will make multiple visits to the clinic, and a final visit 4 weeks after last dose of study drug for a follow-up assessment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Relugolix | Relugolix tablets |
| DRUG | Relugolix Placebo | Relugolix placebo-matching tablets |
| DRUG | Leuprorelin | Leuprorelin injection |
| DRUG | Leuprorelin Placebo | Leuprorelin placebo-matching injections |
Timeline
- Start date
- 2016-03-05
- Primary completion
- 2017-05-17
- Completion
- 2017-09-25
- First posted
- 2016-01-13
- Last updated
- 2019-03-22
- Results posted
- 2019-03-22
Locations
25 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02655237. Inclusion in this directory is not an endorsement.